Benjamin Leder
MGH · Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Benjamin Leder as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:23 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06558188 · Combined Anabolic TherapyMassachusetts General Hospital · recruiting · Osteoporosis, Postmenopausal, Osteoporosis · principal investigator
- N/ANCT05688969 · Mechanisms of Anabolic Osteoporosis TherapyMassachusetts General Hospital · recruiting · Osteoporosis, Postmenopausal · principal investigator
- Ph4NCT05010590 · Anabolic Therapy in Postmenopausal OsteoporosisMassachusetts General Hospital · active not recruiting · Postmenopausal Osteoporosis · principal investigator
- Ph4NCT04026256 · Bone Modeling Effects of Combined Anabolic/Antiresorptive AdministrationMassachusetts General Hospital · completed · Postmenopausal Osteoporosis · principal investigator
- Ph4NCT02176382 · Denosumab and Teriparatide Study (DATA-HD and DATA-EX)Massachusetts General Hospital · completed · Postmenopausal Osteoporosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Combined Anabolic Therapy in Postmenopausal OsteoporosisR21AR083567 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2024 · $587,840 awarded in 2024Grant number is on one of their registry trials
- Limited-duration anabolic therapy in postmenopausal osteoporosisR21AR079718 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2021 to 2023 · $181,120 awarded in 2023Same name and institution; not confirmed by an ID
- Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive AdministrationR01AR073191 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2019 to 2022 · $509,054 awarded in 2022Grant number is on one of their registry trials
- Combination Osteoporosis Therapy and Fracture ReductionR34AR074114 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 to 2019 · $217,544 awarded in 2019Same name and institution; not confirmed by an ID
- Novel combination therapies in the treatment of osteoporosisK24AR067847 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2015 to 2019 · $182,670 awarded in 2019Same name and institution; not confirmed by an ID
- Consolidating Skeletal Benefits after Short-Term Combination Osteoporosis Therapy; The DATA-EX StudyR21AR069871 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2016 to 2018 · $218,535 awarded in 2018Same name and institution; not confirmed by an ID
- Aromatase inhibition in elderly hypogonadal menR01AG025099 · NIA · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2005 to 2009 · $345,552 awarded in 2009Same name and institution; not confirmed by an ID
- CLINICAL TRIAL: ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MENM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2004 to 2008 · $11,980 awarded in 2008Same name and institution; not confirmed by an ID
- DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONEK23RR016310 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2001 to 2005 · $129,951 awarded in 2005Same name and institution; not confirmed by an ID
- DIFFERENTIAL EFFECTS OF ANDROGENS AND ESTROGENS ON BONEF32AR008574 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 1999 to 2000 · $43,348 awarded in 2000Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:23 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- Denosumab in men receiving androgen-deprivation therapy for prostate cancer.N Engl J Med · 2009803 citationsRCR 20.8
- Gonadal steroids and body composition, strength, and sexual function in men.N Engl J Med · 2013556 citationsRCR 21.3
- 459 citationsRCR 18.7
- 361 citationsRCR 13.2
- Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.J Clin Endocrinol Metab · 2014215 citationsRCR 8.3
- Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.J Clin Endocrinol Metab · 2015201 citationsRCR 7.9
- Differential effects of androgens and estrogens on bone turnover in normal men.J Clin Endocrinol Metab · 2003200 citationsRCR 5.2
- Sarcopenia during androgen-deprivation therapy for prostate cancer.J Clin Oncol · 2012171 citationsRCR 4.7
- Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.J Clin Invest · 2016141 citationsRCR 6.2
- Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.J Bone Miner Res · 2015117 citationsRCR 5.0